The treatment landscape of metastatic breast cancer (mBC) is advancing rapidly. Here, Aditya Bardia, MD, MPH, of Massachusetts General Hospital, Boston, MA, discusses therapeutic developments and novel avenues for exploration in the field of mBC. Prof. Bardia highlights PI3K, AKT, HDAC and BCL-2 inhibitors, as well as novel drug combinations, as promising therapies for different types of mBC, including triple negative and HR+/HER2-. He also emphasizes the interest surrounding antibody-drug conjugates, which could increase chemotherapy delivery while maintaining a good toxicity profile.
Metastatic breast cancer: promising therapeutic avenues
